Global Risuteganib in Neurological Disorder Treatment Market, By Type (Angiostatic proteins, Anti-inflammatories, Carboxylic Acids, Eye Disorder Therapies, Neuroprotectants, Oligopeptides, Pyrrolidines, Small Molecules), Application (Dry age-related macular degeneration, Retinal disorders, Wet age-related macular degeneration, Neurological Disorder, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.